These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 12692609)
61. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
62. [Study of the time course of mixed chimerism by fluorescent in situ hybridization in patients with chronic myeloid leukemia after allogenic transplantation of bone marrow]. Vinogradova OA; Savchenko VG; Neverova AL; Diachenko LV; Domracheva EV; Liubimova LS; Mendeleeva LP Ter Arkh; 2001; 73(7):26-34. PubMed ID: 11523405 [TBL] [Abstract][Full Text] [Related]
63. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program. Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y; Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494 [TBL] [Abstract][Full Text] [Related]
65. [HLA-identical sibling allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia in first chronic phase. Analysis of 51 cases]. He Y; Feng SZ; Wang M; Wei JL; Qin TJ; Zhou Z; Zhai WJ; Qiu LG; Han MZ Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):389-92. PubMed ID: 16251016 [TBL] [Abstract][Full Text] [Related]
66. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Nakai K; Mineishi S; Kami M; Saito T; Hori A; Kojima R; Imataki O; Hamaki T; Yoshihara S; Ohnishi M; Kim SW; Ando T; Fumitoh A; Kanda Y; Makimoto A; Tanosaki R; Kanai S; Heike Y; Ohnishi T; Kawano Y; Wakasugi H; Takaue Y Transplantation; 2003 Jun; 75(12):2135-43. PubMed ID: 12829926 [TBL] [Abstract][Full Text] [Related]
67. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions. Fuchs EJ; Seber A; Altomonte V; Braine HG; Humphrey RL; Jones RJ; Noga SJ; Schepers K; Wright SK; Vogelsang GB Bone Marrow Transplant; 1998 Aug; 22(3):303-5. PubMed ID: 9720749 [TBL] [Abstract][Full Text] [Related]
68. Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions. Cwynarski K; Goulding R; Pocock C; Dazzi F; Craddock C; Kaeda J; Olavarria E; Kanfer E; Apperley J; Lawler M; Goldman JM Bone Marrow Transplant; 2001 Sep; 28(6):581-6. PubMed ID: 11607771 [TBL] [Abstract][Full Text] [Related]
69. Donor leukocyte infusions for multiple myeloma. Salama M; Nevill T; Marcellus D; Parker P; Johnson M; Kirk A; Porter D; Giralt S; Levine JE; Drobyski W; Barrett AJ; Horowitz M; Collins RH Bone Marrow Transplant; 2000 Dec; 26(11):1179-84. PubMed ID: 11149728 [TBL] [Abstract][Full Text] [Related]
70. [Therapeutic effect of donor leukocyte transfusion in relapsing marrow transplants in Japan]. Shiobara S; Takahasi S; Yabe H; Maruta I; Kodera Y Rinsho Ketsueki; 1997 Nov; 38(11):1162-9. PubMed ID: 9423332 [TBL] [Abstract][Full Text] [Related]
71. [Therapeutic efficacy of hematopoietic stem cell transplantation in patients with chronic myelogenous leukemia]. Liu QF; Fan ZP; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY Di Yi Jun Yi Da Xue Xue Bao; 2004 Nov; 24(11):1227-9, 1241. PubMed ID: 15567763 [TBL] [Abstract][Full Text] [Related]
72. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy. Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498 [TBL] [Abstract][Full Text] [Related]
74. [Nonmyleoablative allogeneic stem cell transplantation combined with imatinib in treatment of chronic myeloid leukemia: a clinical study]. Liu L; Liu Q; Hao MW; Chen RA; Zhang JL; Wang LH; He H; Jiang SS; Liang YM Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(16):1102-5. PubMed ID: 16029566 [TBL] [Abstract][Full Text] [Related]
75. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. van de Donk NW; Kröger N; Hegenbart U; Corradini P; San Miguel JF; Goldschmidt H; Perez-Simon JA; Zijlmans M; Raymakers RA; Montefusco V; Ayuk FA; van Oers MH; Nagler A; Verdonck LF; Lokhorst HM Bone Marrow Transplant; 2006 Jun; 37(12):1135-41. PubMed ID: 16757975 [TBL] [Abstract][Full Text] [Related]
76. Unexpected late graft failure 9 months after HLA-identical bone marrow transplant (BMT) for chronic myeloid leukemia (CML): treatment with a second BMT. Gil-Fernández JJ; Arranz R; Cámara R; Alegre A; Figuera A; Fernández-Rañada JM Haematologica; 1998 Mar; 83(3):285-7. PubMed ID: 9580418 [TBL] [Abstract][Full Text] [Related]
77. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Bornhäuser M; Kröger N; Schwerdtfeger R; Schafer-Eckart K; Sayer HG; Scheid C; Stelljes M; Kienast J; Mundhenk P; Fruehauf S; Kiehl MG; Wandt H; Theuser C; Ehninger G; Zander AR; Eur J Haematol; 2006 Jan; 76(1):9-17. PubMed ID: 16343266 [TBL] [Abstract][Full Text] [Related]
78. Discrepancy between serological complete remission and concomitant new bone lytic lesions after infusion of escalating low doses of donor lymphocytes in multiple myeloma: a case report. Rondelli D; Bandini G; Cavo M; Re F; Motta M; Senese B; Leopardi G; Stanzani M; Tura S Bone Marrow Transplant; 1999 Sep; 24(6):685-7. PubMed ID: 10490737 [TBL] [Abstract][Full Text] [Related]
79. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy]. Michallet AS; Nicolini F; Michallet M Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766 [TBL] [Abstract][Full Text] [Related]
80. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program. Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]